American Association for Cancer Research
ccr-23-3077_supplementary_table_s9_suppts9.xlsx (9.98 kB)

Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma

Download (9.98 kB)
posted on 2024-07-01, 08:40 authored by Tanner M. Johanns, Elizabeth A.R. Garfinkle, Katherine E. Miller, Alexandra J. Livingstone, Kaleigh F. Roberts, Lakshmi P. Rao Venkata, Joshua L. Dowling, Michael R. Chicoine, Ralph G. Dacey, Gregory J. Zipfel, Albert H. Kim, Elaine R. Mardis, Gavin P. Dunn

Immunohistochemistry (IHC) quantification of CD3+ and CD8+ T cells from tumor blocks


National Institute of Neurological Disorders and Stroke (NINDS)

United States Department of Health and Human Services

Find out more...

The Schnuck Family Fund

The Knight and Christopher Davidson Family Fund

Nationwide Foundation Innovation Fund

National Institutes of Health (NIH)

The Alvin J. Siteman Cancer Center Investment Program

The Foundation for Barnes-Jewish Hospital



Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options due to the lack of tumor immunogenicity. Several clinical trials have reported promising results with cancer vaccines. To date, studies have used data from a single tumor site to identify targetable antigens, but this approach limits the antigen pool and is antithetical to the heterogeneity of GBM. We have implemented multisector sequencing to increase the pool of neoantigens across the GBM genomic landscape that can be incorporated into personalized peptide vaccines called NeoVax. In this study, we report the findings of four patients enrolled onto the NeoVax clinical trial (NCT0342209). Immune reactivity to NeoVax neoantigens was assessed in peripheral blood mononuclear cells pre- and post-NeoVax for patients 1 to 3 using IFNγ-ELISPOT assay. A statistically significant increase in IFNγ producing T cells at the post-NeoVax time point for several neoantigens was observed. Furthermore, a post-NeoVax tumor biopsy was obtained from patient 3 and, upon evaluation, revealed evidence of infiltrating, clonally expanded T cells. Collectively, our findings suggest that NeoVax stimulated the expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine–based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in patients with GBM.